Blueprint Medicines (NASDAQ:BPMC) Price Target Raised to $125.00 at Oppenheimer

Blueprint Medicines (NASDAQ:BPMCFree Report) had its price target increased by Oppenheimer from $114.00 to $125.00 in a report released on Monday, Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

Several other equities analysts have also recently issued reports on the company. HC Wainwright raised their price objective on Blueprint Medicines from $125.00 to $135.00 and gave the stock a buy rating in a research note on Friday, May 3rd. Wedbush reaffirmed an outperform rating and set a $110.00 target price on shares of Blueprint Medicines in a report on Friday, April 26th. Needham & Company LLC reissued a buy rating and issued a $130.00 price target on shares of Blueprint Medicines in a research note on Friday, June 28th. SVB Leerink raised Blueprint Medicines from an underperform rating to a market perform rating and lifted their price target for the stock from $50.00 to $97.00 in a research note on Monday, May 6th. Finally, The Goldman Sachs Group lifted their price target on Blueprint Medicines from $121.00 to $168.00 and gave the company a buy rating in a report on Monday, May 6th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Blueprint Medicines presently has an average rating of Moderate Buy and an average target price of $112.87.

View Our Latest Stock Report on BPMC

Blueprint Medicines Stock Performance

NASDAQ:BPMC opened at $115.95 on Monday. The stock has a market cap of $7.26 billion, a PE ratio of -24.11 and a beta of 0.63. Blueprint Medicines has a fifty-two week low of $43.89 and a fifty-two week high of $119.30. The firm’s fifty day simple moving average is $106.45 and its 200-day simple moving average is $94.13. The company has a quick ratio of 3.61, a current ratio of 3.76 and a debt-to-equity ratio of 0.67.

Blueprint Medicines (NASDAQ:BPMCGet Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($1.32) EPS for the quarter, beating the consensus estimate of ($1.64) by $0.32. Blueprint Medicines had a negative net margin of 102.15% and a negative return on equity of 193.48%. The firm had revenue of $96.12 million for the quarter, compared to analyst estimates of $82.58 million. Analysts expect that Blueprint Medicines will post -5.15 earnings per share for the current fiscal year.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, insider Percy H. Carter sold 4,000 shares of the stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $105.13, for a total value of $420,520.00. Following the transaction, the insider now owns 41,895 shares in the company, valued at $4,404,421.35. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Blueprint Medicines news, insider Percy H. Carter sold 4,000 shares of the firm’s stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $105.13, for a total value of $420,520.00. Following the completion of the sale, the insider now directly owns 41,895 shares of the company’s stock, valued at $4,404,421.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Debra Durso-Bumpus sold 8,817 shares of Blueprint Medicines stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of $111.29, for a total value of $981,243.93. Following the sale, the insider now directly owns 43,763 shares of the company’s stock, valued at approximately $4,870,384.27. The disclosure for this sale can be found here. In the last quarter, insiders have sold 141,898 shares of company stock worth $14,957,242. Insiders own 4.21% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Covestor Ltd increased its holdings in Blueprint Medicines by 9,700.0% during the 1st quarter. Covestor Ltd now owns 294 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 291 shares during the period. Headlands Technologies LLC increased its stake in shares of Blueprint Medicines by 105.2% in the 1st quarter. Headlands Technologies LLC now owns 667 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 342 shares in the last quarter. Compass Wealth Management LLC purchased a new stake in shares of Blueprint Medicines in the 4th quarter worth $69,000. Natixis purchased a new stake in shares of Blueprint Medicines in the 1st quarter worth $73,000. Finally, Van ECK Associates Corp boosted its holdings in Blueprint Medicines by 28.4% in the 4th quarter. Van ECK Associates Corp now owns 872 shares of the biotechnology company’s stock worth $80,000 after buying an additional 193 shares during the period.

Blueprint Medicines Company Profile

(Get Free Report)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.

Featured Stories

Analyst Recommendations for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.